Netherlands· NL-2d67fd44f540
Axumin 3200 MBq/ml oplossing voor injectie
A fluciclovine (18f) product containing fluciclovine [18f], registered in Netherlands by Blue Earth Diagnostics Ireland Ltd. The same ATC class is registered in 10 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Fluciclovine (18f) is registered in 10 of 19 countries.
Countries holding a registration under ATC V09IX12 (fluciclovine (18f)), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 7 of them publish a price we can compare per daily dose
Fluciclovine (18f) · ATC V09IX12
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- FLUCICLOVINE [18F]
- Manufacturer
- Blue Earth Diagnostics Ireland Ltd
- Country
- Netherlands (NL)
- ATC code
- V09IX12
- ATC class
- Fluciclovine (18F)
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/17/1186
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Fluciclovine (18f) in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaAXUMINBlue Earth Diagnostics Ireland Ltd, Dublin
- BelgiumRadelumin 1300 MBq/mlAbx Advanced Biochemical Compounds - Biomedizinische Forschungsreagenzien
- FranceAXUMIN 1600 MBq/mL, solution injectableBLUE EARTH DIAGNOSTICS (ROYAUME UNI)
- IrelandAxumin 1,600 MBq/mL solution for injectionBlue Earth Diagnostics Ireland Ltd
- NorwayAxuminBlue Earth Diagnostics Ireland Ltd
- SwedenAxumin 1600 MBq/ml Injektionsvätska, lösningBlue Earth Diagnostics Ireland Ltd
- FinlandAxuminBlue Earth Diagnostics Ireland Ltd
- GermanyRadeluminAbx Advanced Biochemical Compounds Biomedizinische Forschungsreagenzien Gmbh
Authorised across Europe · EMA
The same active substance is authorised in 13 EEA countries. Names it is sold under:
- Austria · Radelumin
- Belgium · Radelumin
- Germany · Radelumin
- Spain · Radelumin
- France · Radelumin
- Greece · Próstalumin
- Iceland · Axumin
- Italy · Radelumin
- Liechtenstein · Axumin
- Luxembourg · Radelumin
- Norway · Axumin
- Poland · Radelumin
- Portugal · Radelumin
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c6f129ef-1ed4-4311-971b-100cc72b387c GET /v1/drugs/c6f129ef-1ed4-4311-971b-100cc72b387c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Oplossing voor injectie",
"route": "Intraveneus gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/axumin-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Fluciclovine (18F)",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp118634",
"excipients": [
"NATRIUMHYDROXIDE (E 524)",
"TRINATRIUMCITRAAT 2-WATER (E 331)",
"WATER VOOR INJECTIE",
"ZOUTZUUR (E 507)"
],
"substances": [
"FLUCICLOVINE [18F]"
],
"leaflet_url": null,
"authorised_at": "2017/05/22",
"procedure_number": "EMEA/H/C/004197",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/17/1186",
"additional_monitoring": "N"
}See everything about fluciclovine (18f).
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.